PMID- 11691828
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20161124
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 61
IP  - 21
DP  - 2001 Nov 1
TI  - Altered gene expression pattern in cultured human breast cancer cells treated 
      with hepatocyte growth factor/scatter factor in the setting of DNA damage.
PG  - 8022-31
AB  - The cytokine hepatocyte growth factor/scatter factor (HGF/SF) protects epithelial 
      and cancer cells against DNA-damaging agents via a pathway involving signaling 
      from c-Met --> phosphatidylinositol-3- kinase --> c-Akt. However, the downstream 
      alterations in gene expression resulting from this pathway have not been 
      established. On the basis of cDNA microarray and semiquantitative RT-PCR assays, 
      we found that MDA-MB-453 human breast cancer cells preincubated with HGF/SF and 
      then exposed to Adriamycin (ADR), a DNA topoisomerase II inhibitor, exhibit an 
      altered pattern of gene expression, as compared with cells treated with ADR only. 
      [HGF/SF+ADR]-treated cells showed altered expression of genes involved in the DNA 
      damage response, cell cycle regulation, signal transduction, metabolism, and 
      development. Some of these alterations suggest mechanisms by which HGF/SF may 
      exert its protective activity, e.g., up-regulation of polycystic kidney disease-1 
      (a survival-promoting component of cadherin-catenin complexes), down-regulation 
      of 51C (an inositol polyphosphate-5-phosphatase), and down-regulation of TOPBP1 
      (a topoisomerase IIB binding protein). We showed that enforced expression of the 
      cdc42-interacting protein CIP4, a cytoskeleton-associated protein for which 
      expression was decreased in [HGF/SF+ADR]-treated cells, inhibited HGF/SF-mediated 
      protection against ADR. The cDNA microarray approach may open up new avenues for 
      investigation of the DNA damage response and its regulation by HGF/SF.
FAU - Yuan, R
AU  - Yuan R
AD  - Department of Radiation Oncology, Long Island Jewish Medical Center, The Long 
      Island Campus for the Albert Einstein College of Medicine, New Hyde Park, New 
      York 11040, USA.
FAU - Fan, S
AU  - Fan S
FAU - Achary, M
AU  - Achary M
FAU - Stewart, D M
AU  - Stewart DM
FAU - Goldberg, I D
AU  - Goldberg ID
FAU - Rosen, E M
AU  - Rosen EM
LA  - eng
GR  - R01-80000/PHS HHS/United States
GR  - R01-82599/PHS HHS/United States
GR  - R01-ES09169/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (RNA, Messenger)
RN  - 0 (TRIP10 protein, human)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Breast Neoplasms/*genetics/metabolism
MH  - DNA Damage/*physiology
MH  - Doxorubicin/pharmacology
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Hepatocyte Growth Factor/*pharmacology
MH  - Humans
MH  - Microtubule-Associated Proteins/physiology
MH  - Minor Histocompatibility Antigens
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured/drug effects
EDAT- 2001/11/03 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/03 10:00
PHST- 2001/11/03 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/03 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2001 Nov 1;61(21):8022-31.